telmisartan has been researched along with Carcinoma, Hepatocellular in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| El-Gizawy, SA; Essa, EA; Kira, AY; Nasr, M; Saber, S | 2 |
| Chiyo, T; Fujihara, S; Fujita, K; Iwama, H; Kobara, H; Masaki, T; Mori, H; Morishita, A; Nomura, T; Okano, K; Oura, K; Sakamoto, T; Samukawa, E; Suzuki, Y; Tadokoro, T; Yamana, Y; Yoneyama, H | 1 |
| Abdelnasser, A; Abdo, WS; Basuony, M; Eldin, AS; Elsaeed, B; Khodir, AE; Mahmoud, M; Medhat, R; Megahed, N; Nader, K; Saber, S; Salama, MM; Shawky, A; Soliman, WE | 1 |
| Aso, K; Haneda, M; Kanamori, H; Makino, Y; Nakade, Y; Nakao, H; Ohashi, T; Okada, M; Sato, K; Tamaki, Y; Yamauchi, T; Yokohama, S; Yoneda, M | 1 |
| Imaizumi, T; Koga, H; Matsui, T; Nakamura, K; Sata, M; Takeuchi, M; Ueno, T; Yamagishi, S; Yoshida, T | 1 |
6 other study(ies) available for telmisartan and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Telmisartan-Loaded Lactosylated Chitosan Nanoparticles as a Liver Specific Delivery System: Synthesis, Optimization and Targeting Efficiency.
Topics: Carcinoma, Hepatocellular; Chitosan; Drug Carriers; Humans; Lactose; Liver Neoplasms; Nanoparticles; Particle Size; Telmisartan | 2023 |
Lactosylated Chitosan Nanoparticles Potentiate the Anticancer Effects of Telmisartan In Vitro and in a
Topics: Animals; Carcinoma, Hepatocellular; Chitosan; Diethylnitrosamine; Hep G2 Cells; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Mice; Nanoparticles; Telmisartan; Tissue Distribution; Vascular Endothelial Growth Factor A | 2023 |
Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest.
Topics: Benzimidazoles; Benzoates; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Telmisartan | 2017 |
Telmisartan attenuates N-nitrosodiethylamine-induced hepatocellular carcinoma in mice by modulating the NF-κB-TAK1-ERK1/2 axis in the context of PPARγ agonistic activity.
Topics: Animals; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin D1; Diethylnitrosamine; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Matrix Metalloproteinase 2; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; PPAR gamma; Telmisartan; Transcription Factor RelA; Vascular Endothelial Growth Factor A | 2019 |
Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.
Topics: Amino Acids; Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Benzimidazoles; Benzoates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Choline Deficiency; Diet; Drug Evaluation, Preclinical; Fatty Liver; Gene Expression Regulation; Hypoxia-Inducible Factor 1, alpha Subunit; Liver; Liver Cirrhosis; Liver Neoplasms, Experimental; Male; Neovascularization, Pathologic; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Telmisartan; Vascular Endothelial Growth Factor A | 2013 |
Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation.
Topics: Benzimidazoles; Benzoates; C-Reactive Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Glycation End Products, Advanced; Humans; Liver Neoplasms; PPAR gamma; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Telmisartan | 2006 |